ERBB2 and breast cancer: There is growing interest in understanding the importance of low HER2 expression in BC, defined as IHC1+ or 2+ and ISH-negative (HER2/CEP17 ratio < 2.0), as recently highlighted in the last update of the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) [4].